Open AccessLive Attenuated Influenza Vaccination Before 3 Years of Age and Subsequent Development of Asthma
Author(s) -
Roger Baxter,
Ned Lewis,
Bruce Fireman,
John Hansen,
Nicola P. Klein,
Justin R. Ortiz
Publication year - 2018
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000001783
Subject(s) - medicine , live attenuated influenza vaccine , asthma , randomized controlled trial , placebo , hazard ratio , vaccination , pediatrics , confidence interval , influenza vaccine , immunology , alternative medicine , pathology
Live-attenuated influenza vaccines (LAIVs) are not licensed in children younger than 2 years of age because of a wheezing safety signal that has not been fully elucidated. In 2000, the Kaiser Permanente Vaccine Study Center conducted a placebo-controlled randomized clinical trial (RCT) of LAIV in children. As many of these children were still enrolled in Kaiser Permanente in 2014, we could assess the possible long-term association between LAIV and subsequent asthma diagnosis.